Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Bempedoic Acid/Ezetimibe/Atorvastatin FDC
NCT07268625Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bempedoic acid, ezetimibe and atorvastatin in hypercholesterolemia, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Area Under the Curve at 72 hours and Maximum Observed Concentration at 72 hours. Started Dec 2025; status: completed.
02
Drugs
bempedoic acidezetimibeatorvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07268625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07268625.